FDA Approves AstraZeneca's FluMist Nasal Spray for Self-Administration on Friday

Sep 20, 2024, 04:25 PM

The U.S. Food and Drug Administration (FDA) announced on Friday the approval of AstraZeneca's FluMist nasal spray vaccine for self- or caregiver-administration. This vaccine is designed to prevent influenza caused by influenza virus subtypes A and B in individuals aged 2 through 49 years. The approval is part of the FDA's broader effort to expand consumer access to medicines and reduce costs and barriers to care. AstraZeneca's FluMist is the first influenza vaccine approved for self-administration, marking a significant milestone in public health.